亚宝药业
(600351)
| 流通市值：48.02亿 | | | 总市值：48.02亿 |
| 流通股本：6.92亿 | | | 总股本：6.92亿 |
| 利润表 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 营业总收入 | 1,663,165,185.78 | 1,144,946,503.15 | 572,022,344.93 | 2,240,063,505.22 |
| 营业总成本 | 1,338,448,847.99 | 916,155,852.99 | 446,340,355.85 | 1,910,000,308.4 |
| 其他经营收益 | | | | |
| 营业利润 | 325,087,744.55 | 231,268,446.14 | 124,375,564.8 | 370,838,777.51 |
| 利润总额 | 322,873,240.67 | 229,313,553.36 | 124,752,579.32 | 374,457,679.18 |
| 净利润 | 256,745,998.05 | 179,231,159.91 | 106,973,014.22 | 299,899,277.67 |
| 每股收益 | | | | |
| 其他综合收益 | 1,363,821.68 | 1,363,821.68 | - | -3,161,788.86 |
| 综合收益总额 | 258,109,819.73 | 180,594,981.59 | 106,973,014.22 | 296,737,488.81 |
| 资产负债表 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 流动资产: | | | | |
| 流动资产合计 | 1,547,511,369.57 | 1,602,122,193.46 | 1,604,430,645.51 | 1,578,071,210.88 |
| 非流动资产: | | | | |
| 非流动资产合计 | 1,626,674,044.59 | 1,650,341,182.08 | 1,674,286,484.21 | 1,708,175,376.22 |
| 资产总计 | 3,174,185,414.16 | 3,252,463,375.54 | 3,278,717,129.72 | 3,286,246,587.1 |
| 流动负债: | | | | |
| 流动负债合计 | 442,088,452.03 | 420,707,815.95 | 409,770,820.95 | 385,235,715.56 |
| 非流动负债: | | | | |
| 非流动负债合计 | 34,449,508.49 | 68,223,057.73 | 75,235,767.38 | 75,873,335.17 |
| 负债合计 | 476,537,960.52 | 488,930,873.68 | 485,006,588.33 | 461,109,050.73 |
| 所有者权益(或股东权益): | | | | |
| 归属于母公司股东权益合计 | 2,756,603,408.97 | 2,821,003,410.63 | 2,852,505,393.9 | 2,884,243,117.79 |
| 股东权益合计 | 2,697,647,453.64 | 2,763,532,501.86 | 2,793,710,541.39 | 2,825,137,536.37 |
| 负债和股东权益合计 | 3,174,185,414.16 | 3,252,463,375.54 | 3,278,717,129.72 | 3,286,246,587.1 |
| 现金流量表 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 经营活动产生的现金流量: | | | | |
| 经营活动现金流入小计 | 1,686,172,136.06 | 1,135,558,939.77 | 558,216,210.28 | 2,305,428,374.69 |
| 经营活动现金流出小计 | 1,160,521,993.89 | 782,697,154.24 | 371,780,973.01 | 1,731,662,660.66 |
| 经营活动产生的现金流量净额 | 525,650,142.17 | 352,861,785.53 | 186,435,237.27 | 573,765,714.03 |
| 投资活动产生的现金流量: | | | | |
| 投资活动现金流入小计 | 228,669,889.87 | 217,606,480.9 | 210,160,407.53 | 273,159,895.95 |
| 投资活动现金流出小计 | 239,589,353.39 | 226,619,354.62 | 216,241,261.91 | 176,659,172.07 |
| 投资活动产生的现金流量净额 | -10,919,463.52 | -9,012,873.72 | -6,080,854.38 | 96,500,723.88 |
| 筹资活动产生的现金流量: | | | | |
| 筹资活动现金流入小计 | - | - | - | 193,982,865.04 |
| 筹资活动现金流出小计 | 423,371,615.41 | 244,108,626.49 | 139,341,307.7 | 622,034,697.14 |
| 筹资活动产生的现金流量净额 | -423,371,615.41 | -244,108,626.49 | -139,341,307.7 | -428,051,832.1 |
| 汇率变动对现金及现金等价物的影响 | -70,397.32 | -50,330.18 | -31,527.49 | 39,904.78 |
| 现金及现金等价物净增加额 | 91,288,665.92 | 99,689,955.14 | 40,981,547.7 | 242,254,510.59 |
| 期末现金及现金等价物余额 | 911,801,177.61 | 920,202,466.83 | 861,494,059.39 | 820,512,511.69 |
| 补充资料: | | | | |
| 现金及现金等价物的净增加额 | - | 99,689,955.14 | - | 242,254,510.59 |